Infectious Disease

Displaying 1 - 9 of 9


Human antibodies targeting a novel flu epitope for use as a universal flu vaccine and treatment

Scientists at Vanderbilt have discovered a new class of human antibodies specific to a novel target for the detection, prevention, and treatment of influenza A viruses (IAV). Using structural characterization, they have identified a novel antigenic site on the hemagglutin (HA) head domain that may be targeted by multiple antibodies simultaneously in a non-competitive manner. They found that administration of these antibodies against an otherwise lethal challenge with viruses of H1N1, H3N2, H5N1, or H7N9 subtypes confers protection when used as prophylaxis or therapy against major IAV subtypes that are pathogenic to humans. These antibodies may prove effective as a universal influenza treatment or in the design of a universal influenza vaccine.


Licensing Contact

Jody Hankins

615.322.5907

Inventors

James Crowe, Seth Zost

New antibiotics against new targets in multi-drug resistant microorganisms

New everninomicin antibiotics including a potent bifunctional antibiotic natural product targeting two different and distant ribosomal sites are under development and can be readily produced using synthetic biology. Developing resistance to this bidentate antibiotic should be very difficult for pathogenic microorganisms.


Licensing Contact

Jody Hankins

615.322.5907
Therapeutics
Infectious Disease

Animal Health: Control of Insect Populations via Wolbachia or Bacteriophage Tools

The insect microbiome is a rich resource that can explored to control insect reproduction and insect populations at large. Vanderbilt University has a collection of technologies available for such purposes, including bacteriophage therapies, Wolbachia genomic editing techniques and tools, and transgenic insect approaches.


Licensing Contact

Jody Hankins

615.322.5907

Agriculture: Control of Insect Populations via Wolbachia or Bacteriophage Tools

The insect microbiome is a rich resource that can explored to control insect reproduction and insect populations at large. Vanderbilt University has a collection of technologies available for such purposes, including bacteriophage therapies, Wolbachia genomic editing techniques and tools, and transgenic insect approaches.


Licensing Contact

Jody Hankins

615.322.5907

New Clostridium Difficile Recombinant Toxin for Safe Vaccine Development

A structural biology approach has identified a conserved region common to multiple Clostridium toxins. Specific mutations of the protein sequence in this region prevent the toxins from entering into intestinal cells, thereby preventing widespread tissue damage. These recombinant Clostridium toxins may be used to create a multivalent vaccine to protect against multiple species of Clostridium. Furthermore, the recombinant toxin may be used as a safer alternative to the native toxins in vaccine manufacturing. This discovery stems from a collaboration between the laboratories of Dr. Borden Lacy of Vanderbilt University and Dr. Roman Melnyk of the Hospital for Sick Children.


Licensing Contact

Jody Hankins

615.322.5907

Inhibitors of Inward-Rectifying Potassium Channels (Insecticide)

This research targets IRK.


Licensing Contact

Tom Utley

615.343.3852

Luciferase Reporter System for Viral Detection in Vitro and in Vivo

This research targets Respiratory Syncytial Virus.


Licensing Contact

Taylor Jordan

615.936.7505

Anti-Clostridium Difficile Toxin A (c-terminal) Mouse Monoclonal Antibody

This antibody binds to the delivery domain of Clostridium difficile Toxin A.


Licensing Contact

Jody Hankins

615.322.5907
Research Tools
Antibody
Infectious Disease

Purified Staphylocoagulase Fragment (1-325)

This research targets S. Aureus.


Licensing Contact

Karen Rufus

615.322.4295